Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force

Abstract The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and staging system for cutaneous T-cell lymphoma (CTCL). These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides (MF) and Sézary syndrome (SS) since the 1979 publication of the original guidelines, to clarify certain variables that currently impede effective interinstitution and interinvestigator communication and/or the development of standardized clinical trials in MF and SS, and to provide a platform for tracking other variables of potential prognostic significance. Moreover, given the difference in prognosis and clinical characteristics of the non-MF/non-SS subtypes of cutaneous lymphoma, this revision pertains specifically to MF and SS. The evidence supporting the revisions is discussed as well as recommendations for evaluation and staging procedures based on these revisions.

Download Full-text

Erratum in Olsen et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713-1722.

Blood ◽

10.1182/blood-2008-02-142653 ◽

2008 ◽

Vol 111 (9) ◽

pp. 4830-4830

Keyword(s):

Mycosis Fungoides ◽

International Society ◽

Task Force ◽

Cutaneous Lymphoma ◽

Sézary Syndrome ◽

Sezary Syndrome ◽

European Organization ◽

Cutaneous Lymphomas

Download Full-text

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(08)70989-4 ◽

2008 ◽

Vol 2008 ◽

pp. 388-389

Author(s):

B.H. Thiers

Keyword(s):

Mycosis Fungoides ◽

International Society ◽

Task Force ◽

Cutaneous Lymphoma ◽

Sézary Syndrome ◽

Sezary Syndrome ◽

European Organization ◽

Cutaneous Lymphomas

Download Full-text

Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2010.32.0630 ◽

2011 ◽

Vol 29 (18) ◽

pp. 2598-2607 ◽

Cited By ~ 300

Author(s):

Elise A. Olsen ◽

Sean Whittaker ◽

Youn H. Kim ◽

Madeleine Duvic ◽

H. Miles Prince ◽

...

Keyword(s):

Clinical Trials ◽

Mycosis Fungoides ◽

The United States ◽

Cutaneous Lymphoma ◽

Response Criteria ◽

Sézary Syndrome ◽

Sezary Syndrome ◽

End Points ◽

Cutaneous Lymphomas ◽

Hodgkin's Lymphomas

Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinical trials in MF/SS have suffered from a lack of standardization in evaluation, staging, assessment, end points, and response criteria. Recently defined criteria for the diagnosis of early MF, guidelines for initial evaluation, and revised staging and classification criteria for MF and SS now offer the potential for uniform staging of patients enrolled in clinical trials for MF/SS. This article presents consensus recommendations for the general conduct of clinical trials of patients with MF/SS as well as methods for standardized assessment of potential disease manifestations in skin, lymph nodes, blood, and visceral organs, and definition of end points and response criteria. These guidelines should facilitate collaboration among investigators and collation of data from sponsor-generated or investigator-initiated clinical trials involving patients with MF or SS.

Download Full-text